Welcome to our dedicated page for AGIOS PHARMACEUTICALS SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
Form 144 notice for AGIO (Agios Pharmaceuticals, Inc.) reporting a proposed sale of 3,651 shares of common stock via Morgan Stanley Smith Barney. The filing states the aggregate market value of the shares is $134,247.00 and lists 58,101,518 shares outstanding. The securities were acquired through the vesting of restricted stock units on 09/26/2025 and the same date is shown as the approximate sale date and payment date. The filer reports no securities sold in the past three months.
Theodore James Jr., identified as a Principal Accounting Officer of Agios Pharmaceuticals (AGIO), reported a sale of 8,546 shares of the issuer's common stock on 09/05/2025 at a reported price of $36.87 per share. After the reported transaction, the filing shows 868 shares beneficially owned by the reporting person in a direct form. The disclosure is a standard Section 16 Form 4 reporting an insider sale.
David Scadden, a director of Agios Pharmaceuticals, reported transactions dated 08/27/2025 under a Rule 10b5-1 plan. He exercised an option to acquire 200 shares of common stock at an exercise price of $18.09 and sold 200 shares at $40.00. The Form shows beneficial ownership of common stock of 17,803 shares following the acquisition and 17,603 shares following the sale. The related option was originally granted on June 21, 2022 and vested 100% one year after grant. The filing is signed by William Cook as attorney-in-fact on 08/29/2025.
Paradigm BioCapital and related entities reported beneficial ownership of 3,027,977 shares of Agios Pharmaceuticals common stock, representing 5.2% of the outstanding class. The filing shows the position as of the close of business on August 21, 2025 and explains that the total includes 2,827,977 shares directly held (2,493,645 by Paradigm BioCapital International Fund Ltd. and 334,332 by a separately managed account) plus 200,000 shares underlying call options exercisable within 60 days (176,300 attributable to the Fund and 23,700 to the Account). The reporting group bases percentages on 58,101,518 shares outstanding as of July 25, 2025. The filing states these holdings are not intended to influence control of the issuer and includes a joint filing agreement.
Agios Pharmaceuticals (AGIO) Form 144 notice: The filing reports a proposed sale of 200 common shares through Morgan Stanley Smith Barney on 08/27/2025 with an aggregate market value of $8,000. The shares were acquired the same day by stock option exercise and paid in cash.
The filing also discloses a prior sale by David Scadden of 1,400 common shares on 07/10/2025 for gross proceeds of $56,000. The issuer's outstanding shares are listed as 58,101,518, and the proposed sale is to be executed on the NASDAQ.
Rahul Ballal, a director of Agios Pharmaceuticals (AGIO), reported a transaction dated 08/11/2025 involving restricted stock units and common stock. The filing records a grant of 2,302 restricted stock units, each representing a contingent right to receive one share, originally granted on 08/11/2022; the underlying shares vest in three equal annual installments beginning 08/11/2023. The report shows a price of $0 for the restricted units.
Following the reported transaction the filing shows Mr. Ballal beneficially owns 12,414 shares of Agios common stock in a direct capacity.
Cynthia Smith, a director of Agios Pharmaceuticals (AGIO), reported the vesting/conversion of 2,302 restricted stock units into common shares on 08/11/2025. The RSUs were granted on 08/11/2022 and, per the filing, vest in three equal annual installments beginning 08/11/2023. The transaction is recorded with transaction code M and shows an acquisition at $0 per share.
The filing reports 12,414 common shares beneficially owned directly by the reporting person following the reported transaction. No cash proceeds or sales are shown in the report, indicating this event reflects equity compensation vesting rather than a market sale.
Brian Goff, Chief Executive Officer and Director of Agios Pharmaceuticals (AGIO) reported transactions on Form 4 dated 08/08/2025. On that date 22,691 restricted stock units vested and were converted into common stock, and 11,085 shares were sold at $36.67 per share to satisfy tax withholding obligations. The sale was executed pursuant to durable automatic sale instructions consistent with a Rule 10b5-1(c) plan included in the reporting person's RSU agreement dated August 8, 2022.
The Form discloses that each RSU represents a contingent right to one share, the RSUs were granted on August 8, 2022, and vest in three equal annual installments beginning August 8, 2023. Following the reported transactions, the filing shows beneficial ownership of 123,528 shares.
Agios Pharmaceuticals filed a Form 144 reporting a proposed sale of 11,085 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $410,810.10 and an approximate sale date of 08/08/2025. The filing shows 58,101,518 shares outstanding, so the proposed sale represents about 0.019% of outstanding shares.
The securities to be sold were recorded as acquired on 08/08/2025 by vesting of restricted stock units from the issuer. The filing also lists a prior sale by Brian Goff of 18,700 shares on 06/24/2025 for $627,198.00. Certain filer-identifying fields (CIK and the named person for whose account the current sale is being made) are not populated in the provided content.